FindTrial
Sign In

A systematic review of the functionality of "passionflower-derived flavonoids" for a function to mitigate temporary declines in vitality in healthy adults (updated version from 2022).

A systematic review of the functionality of "passionflower-derived flavonoids" for a function to mitigate temporary declines in vitality in healthy adults (updated version from 2022). - A systematic review of the functionality of "passionflower-derived flavonoids" for a function to mitigate temporary declines in vitality in healthy adults (updated version from 2022).

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000060203
Enrollment
Unknown
Registered
2025-12-25
Start date
2025-12-25
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The subjects were healthy adults (excluding those under 18 years old, pregnant women, and lactating women)

Interventions

None listed

Sponsors

Oryza Oil and Fat Chemical Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: P-Participant: Participant The subjects were healthy adults (excluding those under 18 years old, pregnant women, and lactating women) I-intervention: Intervention (food) characteristics Continuous intake of passionflower-derived flavonoids, Unlimited dosage forms, period and follow-up period. C-Comparison: Comparison Placebo (The placebo's formulation is not specified) O-Outcome: Outcome The primary outcome: QOL questionnaire (vitality) The secondary outcome: QOL questionnaire (other items) S-Study design: Randomized parallel group controlled trials, randomized crossover trials, quasi-randomized parallel group controlled trials, quasi-randomized crossover trials, non-randomized parallel group controlled trials, non-randomized crossover trials or open trial

Exclusion criteria

Exclusion criteria: The literature which does not meet PICOS, such as conference abstracts (conference proceedings) that are not original articles will be excluded.

Design outcomes

Primary

MeasureTime frame
QOL questionnaire (vitality)—

Secondary

MeasureTime frame
QOL questionnaire (other items)—

Countries

Japan

Contacts

Public ContactMakiko Hashimoto

Oryza Oil and Fat Chemical Co., Ltd. Planning & Solution Development Department Section

kaihatsu@mri.biglobe.ne.jp0586-86-5141

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026